Heparin-induced thrombocytopenia: analysis of risk factors in medical inpatients

British Journal of Haematology

Volumn 154, Issue 3, 2011, Pages 373-377

  Kato, Shumei ^a,b   Takahashi, Koichi ^a   Ayabe, Kengo ^a   Samad, Reza ^a   Fukaya, Eri ^a   Friedmann, Patricia ^a   Varma, Mala ^c   Bergmann, Steven R ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NIPPON MEDICAL SCHOOL   (Japan)

^c Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Heparin induced thrombocytopenia; In patient; Medicine; Platelet; Risk factor

Indexed keywords

ARGATROBAN; ENOXAPARIN; HEPARIN; LEPIRUDIN; THROMBIN INHIBITOR;

ADULT; ANTICOAGULATION; ARTICLE; ASTHMA; AUTOIMMUNE DISEASE; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; FEMALE; GOUT; HEART FAILURE; HEMODIALYSIS PATIENT; HEPARIN INDUCED THROMBOCYTOPENIA; HOSPITAL PATIENT; HUMAN; HYPERTENSION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SYNDROME CREST; THROMBOCYTE COUNT; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; COMORBIDITY; CONFOUNDING FACTORS (EPIDEMIOLOGY); DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPARIN; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NEW YORK CITY; PLATELET COUNT; RENAL DIALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOCYTOPENIA;

EID: 79960260452     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08746.x     Document Type: Article

References (23)

1. Arepally, G.M. & Ortel, T.L. (2006) Clinical practice. Heparin-induced thrombocytopenia. New England Journal of Medicine, 355, 809-817.
2. Asmis, L.M., Segal, J.B., Plantinga, L.C., Fink, N.E., Kerman, J.S., Kickler, T.S., Coresh, J. & Gardner, L.B. (2008) Heparin-induced antibodies and cardiovascular risk in patients on dialysis. Thrombosis and Haemostasis, 100, 498-504.
3. Brieger, D.B., Mak, K.H., Kottke-Marchant, K. & Topol, E.J. (1998) Heparin-induced thrombocytopenia. Journal of the American College of Cardiology, 31, 1449-1459.
4. Flanigan, M.J., Von Brecht, J., Freeman, R.M. & Lim, V.S. (1987) Reducing the hemorrhagic complications of hemodialysis: a controlled comparison of low-dose heparin and citrate anticoagulation. American Journal of Kidney Diseases, 9, 147-153.
5. Girolami, B., Prandoni, P., Stefani, P.M., Tanduo, C., Sabbion, P., Eichler, P., Ramon, R., Baggio, G., Fabris, F. & Girolami, A. (2003) The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood, 101, 2955-2959.
6. Greinacher, A., Juhl, D., Strobel, U., Wessel, A., Lubenow, N., Selleng, K., Eichler, P. & Warkentin, T.E. (2007) Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. Journal of Thrombosis and Haemostasis, 5, 1666-1673.
7. Lindhoff-Last, E., Nakov, R., Misselwitz, F., Breddin, H.K. & Bauersachs, R. (2002) Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin. British Journal of Haematology, 118, 1137-1142.
8. Martel, N., Lee, J. & Wells, P.S. (2005) Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood, 106, 2710-2715.
9. Mehta, R.L., McDonald, B.R., Aguilar, M.M. & Ward, D.M. (1990) Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney International, 38, 976-981.
10. Panush, R.S., Edwards, N.L., Longley, S. & Webster, E. (1988) 'Rhupus' syndrome. Archives of Internal Medicine, 148, 1633-1636.
11. Pinnick, R.V., Wiegmann, T.B. & Diederich, D.A. (1983) Regional citrate anticoagulation for hemodialysis in the patient at high risk for bleeding. New England Journal of Medicine, 308, 258-261.
12. Pouplard, C., May, M.A., Iochmann, S., Amiral, J., Vissac, A.M., Marchand, M. & Gruel, Y. (1999a) Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. Circulation, 99, 2530-2536.
13. Pouplard, C., Amiral, J., Borg, J.Y., Laporte-Simitsidis, S., Delahousse, B. & Gruel, Y. (1999b) Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia. American Journal of Clinical Pathology, 111, 700-706.
14. Price, E.A., Hayward, C.P., Moffat, K.A., Moore, J.C., Warkentin, T.E. & Zehnder, J.L. (2007) Laboratory testing for heparin-induced thrombocytopenia is inconsistent in North America: a survey of North American specialized coagulation laboratories. Thrombosis and Haemostasis, 98, 1357-1361.
15. Ringel, R.A., Brick, J.E., Brick, J.F., Gutmann, L. & Riggs, J.E. (1990) Muscle involvement in the scleroderma syndromes. Archives of Internal Medicine, 150, 2550-2552.
16. Smythe, M.A., Koerber, J.M. & Mattson, J.C. (2007) The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospital. Chest, 131, 1644-1649.
17. Warkentin, T.E. (2004) Heparin-induced thrombocytopenia: diagnosis and management. Circulation, 110, e454-e458.
18. Warkentin, T.E. & Eikelboom, J.W. (2007) Who is (still) getting HIT? Chest, 131, 1620-1622.
19. Warkentin, T.E. & Kelton, J.G. (2001) Temporal aspects of heparin-induced thrombocytopenia. New England Journal of Medicine, 344, 1286-1292.
20. Warkentin, T.E., Levine, M.N., Hirsh, J., Horsewood, P., Roberts, R.S., Gent, M. & Kelton, J.G. (1995) Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. New England Journal of Medicine, 332, 1330-1335.
21. Warkentin, T.E., Sheppard, J.A., Moore, J.C., Moore, K.M., Sigouin, C.S. & Kelton, J.G. (2005) Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? Journal of Laboratory and Clinical Medicine, 146, 341-346.
22. Warkentin, T.E., Sheppard, J.A., Sigouin, C.S., Kohlmann, T., Eichler, P. & Greinacher, A. (2006) Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood, 108, 2937-2941.
23. Warkentin, T.E., Greinacher, A., Koster, A. & Lincoff, A.M. (2008) Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 133, 340S-380S.